Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1and P2Y12receptors: A new finding that may influence the design of anti-thrombotic agents
Authors:
- J. R. GlennJGJ. R. Glenn
- S. C. FoxSFS. C. Fox
- J. A. MayJMJ. A. May
- N. L. DovlatovaNDN. L. Dovlatova
- S.-W. TangSTS.-W. Tang
- N. R. ThomasNTN. R. Thomas
- V. RalevicVRV. Ralevic
- S. HeptinstallSHS. Heptinstall
- 1 January 2008
- journal article
- Published by Taylor & Francis in Platelets
- Vol. 19 (2) , 134-145
Abstract
We have performed a detailed investigation of the effects on platelet function of coenzyme A (CoA) and several acyl-CoAs. Platelet aggregation was measured by turbidimetry and by platelet counting; platelet shape change was measured using light scattering; P-selectin, Ca2+ mobilization and vasodilator-stimulated phosphoprotein (VASP) phosphorylation were measured by flow cytometry. The compounds investigated inhibited ADP-induced platelet aggregation; those with saturated acyl groups containing 16-18 carbons were most effective. The effects of palmitoyl-CoA (16:0) were studied in depth. It inhibited platelet shape change and Ca2+ mobilization brought about by ADP (but not other agonists) indicating antagonism at P2Y(1) receptors, and also inhibited ADP-induced P-selectin expression. Effects of palmitoyl-CoA on the platelet aggregation and Ca2+ mobilization induced by several different agonists and agonist combinations were compared with those of MRS 2179 (a P2Y(1) antagonist) and AR-C69931 (a P2Y(12) antagonist), and were consistent with palmitoyl-CoA acting mainly at P2Y(1) but also with partial antagonism at P2Y(12) receptors. Antagonism at P2Y(12) receptors was confirmed in studies of VASP-phosphorylation. Palmitoyl-CoA did not act as an antagonist at P2X(1) receptors. The results are discussed in relation to the possibility that acyl-CoAs may contribute as endogenous modulators of platelet function and might serve as lead compounds for the design of novel antithrombotics.Keywords
This publication has 20 references indexed in Scilit:
- Preclinical and Clinical Studies with Selective Reversible Direct P2Y12AntagonistsSeminars in Thrombosis and Hemostasis, 2005
- Coenzyme A: Back in actionProgress in Lipid Research, 2005
- Inhibitory effects of P2Y12receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromesPlatelets, 2005
- Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometryPlatelets, 2004
- Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart diseasePlatelets, 2002
- Specific Impairment of Human Platelet P2Y AC ADP Receptor–Mediated Signaling by the Antiplatelet Drug ClopidogrelArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Release of fatty acid-binding protein and long chain fatty acids from isolated rat heart after ischemia and subsequent calcium paradoxMolecular and Cellular Biochemistry, 1993
- Significance of cytoplasmic fatty acid-binding protein for the ischemic heartMolecular and Cellular Biochemistry, 1993
- Platelet aggregation is inhibited by long chain acyl-CoABiochemical and Biophysical Research Communications, 1988
- Inhibition of platelet aggregation by acyl-CoA thioestersBiochimica et Biophysica Acta (BBA) - General Subjects, 1976